Reduction of seminal vesicle after androgen deprivation therapy:effects of neo-adjuvant or monal therapy to the target volume of seminal vesicles in prostate cancer radiotherapy
Department of Radiation Oncology,First Hospital of Peking University,100034 Beijing,China (Qi X,Gao XSH,Li FY,Zhang M,Li HZH,Zhao B,Ma MW);Rush University Medical Center, Chicago,USA (Wang D)
Abstract：Objective To clarify the morphological reduction of seminal vesicle (SV) after neo-adjuvant androgen deprivation (NHT),and determine the optimal SV target volume for prostate cancer radiotherapy. Methods MR images both before and after NHT (median 5 months) were collected from thirty-one patients with cT2-4N0M0 prostate cancer. SV volume was measured in axial T1WI,while SV length was obtained in a reconstructed oblique coronary plane through its long axial from a 3D sequence. The difference was analyzed with paired t-test method. Results SV significantly decreased after NHT (volume:(12.5±4.5) cm2 to (7.3±2.1) cm2,length:(34.1±5.7) mm to (29.7±5.2) mm).The reduction rate of volume,length,anterior-posterior diameter and left-right diameter was (39.3±13.6)%,(12.9±5.2)%,(26.2±9.8)%,(17.4±11.0)%,respectively. For SV with and without MR detected involvement,length shortening were (16.7±4.8)% and (11.1±4.4)%(P=0.000);for involved SV and lesions within,volume reduction were (41.0±16.0)% and (66.3±14.4)%(P=0.000),both indicating a more sensitive response to NHT of the involved portion than normal SV.40%(8/20) SV showed diffuse lower signal but no residual lesion after NHT. Conclusions After NHT the SV volume shrinkage was obviously,which may reduce the SV target volume and enable sparing of the surrounding normal tissues. Compare with the anterior-posterior diameter and left-right diameter,the reduction rate of the length is smaller,which suggests that it may be not reasonable to reduce the extent of SV included into CTV for the patients who have received NHT.
Qi Xin,Gao Xianshu,Li Feiyu et al. Reduction of seminal vesicle after androgen deprivation therapy:effects of neo-adjuvant or monal therapy to the target volume of seminal vesicles in prostate cancer radiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(2): 135-139.
[1]Katcher J,Kupelian PA,Zippe C,et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone[J].Int J Radiat Oncol Biol Phys,1997,37(4):871-876. [2]Partin AW,Mangold LA,Lamm DM,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium[J].Urology,2001,58(6):843-848. [3]D′amico AV,Whittington R,Kaplan I,et al. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV[J].Int J Radiat Oncol Biol Phys,1997,39(2):335-340. [4]Pisansky TM,Zincke H,Suman VJ,et al. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens[J].Int J Radiat Oncol Biol Phys,1996,34(1):33-39. [5]Zlotta AR,Roumeguère T,Ravery V,et al. Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy？A multivariate analysis on 1283 patients[J].Eur Urol,2004,46(1):42-49. [6]Kestin L,Goldstein N,Vicini F,et al. Treatment of prostate cancer with radiotherapy:should the entire seminal vesicles be included in the clinical target volume?[J].Int J Radiat Oncol Biol Phys,2002,54(3):686-697. [7]Lawton CA,DeSilvio M,Roach Ⅲ M,et al. An update of the phase Ⅲ trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvanttotal androgen suppression:updated analysis of RTOG 94-13,withemphasison unexpected hormone/radiation interactions[J].Int J Radiat Oncol Biol Phys,2007,69(3):646-655.
[8]Denham JW,Steigler A,Lamb DS,et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer:10-year data from the TROG 96.01 randomised trial[J].Lancet Oncol,2011,12(5):451-459.DOI:10.1016/S1470-2045(11)70063-8. [9]Hanks GE,Pajak TF,Porter A,et al. Phase Ⅲ trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate:the Radiation Therapy Oncology Group Protocol 92–02[J].J Clin Oncol,2003,21(21):3972-3978. [10]Furuya R,Hisasue S,Furuya S,et al. Fate of seminal vesicles and prostate after medical castration:how long is the optimal duration of neoadjuvant treatment for prostate cancer before radiation?[J].Urology,2008,72(2):417-421.DOI:10.1016/j.urology.2007.11.025. [11]Chen M,Hricak H,Kalbhen C,et al. Hormonal ablation of prostatic cancer:effects on prostate morphology,tumor detection,and staging by endorectal coil MR imaging[J].AJR Am J Roentgenol,1996,166(5):1157-1163. [12]Qi X,Gao XS,Asaumi J,et al. Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer:comparison between EORTC prostate cancer radiotherapy guideline,RTOG0815 protocol and actual anatomy[J].Radiat Oncol,2014,9(1):288.DOI:10.1186/s13014-014-0288-1.
2016, Vol. 25 
